Association between serum ferritin and mortality: Findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study

Nephrology Dialysis Transplantation

Volumn 33, Issue 12, 2018, Pages 2234-2244

  Karaboyas, Angelo ^a   Morgenstern, Hal ^b,c   Pisoni, Ronald L ^a   Zee, Jarcy ^a   Vanholder, Raymond ^d   Jacobson, Stefan H ^e   Inaba, Masaaki ^f   Loram, Lisa C ^g   Port, Friedrich K ^b,h   Robinson, Bruce M ^a,h  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Medical School   (United States)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e DANDERYD HOSPITAL   (Sweden)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Keryx Biopharmaceuticals   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anemia; Ferritin; Hemodialysis; Inflammation; Iron; Mortality

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; IRON; BIOLOGICAL MARKER;

ADULT; ANEMIA; ARTICLE; CLINICAL OUTCOME; CLINICAL PRACTICE; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; EUROPE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; INFLAMMATION; JAPAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; UNITED STATES; ADVERSE EVENT; AGED; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL RATE;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA; BIOMARKERS; EUROPE; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; IRON; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 85052504006     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfy190     Document Type: Article

References (45)

1. Locatelli F, Pisoni RL, Akizawa T et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004; 44: 27–33
2. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2017; 7: e1–335
3. Macdougall IC, Bircher AJ, Eckardt K et al. Iron management in chronic kidney disease: conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference. Kidney Int 2016; 89: 28–39
4. Dwyer JP. We give too much intravenous iron. Semin Dial 2016; 29: 309–311
5. Hung S, Tarng D. ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target. Kidney Int 2014; 86: 676–678
6. Charytan DM, Pai AB, Chan CT et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015; 26: 1238–1247
7. Bailie GR, Larkina M, Goodkin DA et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162–168
8. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070–3080
9. Miskulin DC, Tangri N, Bandeen-Roche K et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014; 9: 1930–1939
10. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623–1632
11. Brookhart MA, Schneeweiss S, Avorn J et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303: 857–864
12. Rostoker G, Griuncelli M, Loridon C et al. Reassessment of iron biomarkers for prediction of dialysis iron overload: an MRI study. PLoS One 2015; 10: e0132006
13. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 2006; 1:(Suppl 1) S9–S18
14. Singh AK, Coyne DW, Shapiro W et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163–1171
15. Richardson D, Hodsman A, van Schalkwyk D et al. Management of anaemia in haemodialysis and peritoneal dialysis patients (chapter 8). Nephrol Dial Transplant 2007; 22(Suppl 7): vii78–vii104
16. Ferrari P, Kulkarni H, Dheda S et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 77–83
17. Hamano T, Fujii N, Hayashi T et al. Thresholds of iron markers for iron deficiency erythropoiesis—finding of the Japanese nationwide dialysis registry. Kidney Int Suppl 2015; 5: 23–32
18. Kalantar-Zadeh K, Don BR, Rodriguez RA et al. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001; 37: 564–572
19. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141–149
20. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008; 3: 1691–1701
21. Bazeley J, Bieber BA, Li Y et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2452–2461
22. Ford BA, Coyne DW, Eby CS et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 2009; 75: 104–110
23. Van Wyck DB, Alcorn H, Jr, Gupta R. Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis. Am J Kidney Dis 2010; 56: 540–546
24. Fuller DS, Pisoni RL, Bieber BA et al. The DOPPS practice monitor for US dialysis care: trends through December 2011. Am J Kidney Dis 2013; 61: 342–348
25. Fuller DS, Pisoni RL, Bieber BA et al. The DOPPS practice monitor for US dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 2013; 62: 1213–1220
26. Karaboyas A, Zee J, Morgenstern H et al. Understanding the recent increase in ferritin levels in U.S. dialysis patients: potential impact of changes in IV iron and ESA dosing. Clin J Am Soc Nephrol 2015; 10: 1814–1821
27. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist 2010; 75: 49029–49214
28. Kliger AS, Foley RN, Goldfarb DS et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013; 62: 849–859
29. Locatelli F, Covic A, Eckardt KU et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348–354
30. Locatelli F, Bárány P, Covic A et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346–1359
31. Tsubakihara Y, Nishi S, Akiba T et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14: 240–275
32. Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570–2579
33. Birnie K, Caskey F, Ben-Shlomo Y et al. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13. Nephrol Dial Transplant 2017; 32: 692–698
34. 2012 Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1997-2011. Arbor Research Collaborative for Health, Ann Arbor, MI. dopps.org/annualreport/ (29 July 2016, date last accessed)
35. Young EW, Goodkin DA, Mapes DL et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int 2000; 57(Suppl 74): S74–S81
36. Pisoni RL, Gillespie BW, Dickinson DM et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004; 44: 7–15
37. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer, 2001
38. Raghunathan TE, Solenberger PW, Van Hoewyk J. IVEware: Imputation and Variance Estimation Software: User Guide. Ann Arbor, MI: Institute for Social Research, University of Michigan, 2002
39. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York: Wiley, 1987
40. Maruyama Y, Yokoyama K, Yokoo T et al. The different association between serum ferritin and mortality in hemodialysis and peritoneal dialysis patients using Japanese nationwide dialysis registry. PLoS One 2015; 10: e0143430
41. Kuragano T, Matsumura O, Matsuda A et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2014; 86: 845–854
42. Shoji T, Niihata K, Fukuma S et al. Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation. Clin Exp Nephrol 2017; 21: 685–693
43. Airy M, Mandayam S, Mitani AA et al. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant 2015; 30: 2075–2079
44. Slotki I, Cabantchi ZI. The labile side of iron supplementation in CKD. J Am Soc Nephrol 2015; 26: 2612–2619
45. European Union Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB and http://www.kidneyresearchuk.org/pivotal (10 August 2016, date last accessed)